Moderna (MRNA) Hisse Özeti
Bir biyoteknoloji şirketi olan Moderna, Inc. Amerika Birleşik Devletleri, Avrupa ve uluslararası alanda mesajcı RNA ilaçları sağlamaktadır. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 0/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 3/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden MRNA için herhangi bir risk tespit edilmedi.
MRNA Community Fair Values
Create NarrativeSee what 244 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$175
FV
61.6% değerinin altında içsel indirim910
users have viewed this narrative1users have liked this narrative
1users have commented on this narrative
19users have followed this narrative
Moderna, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$67.27 |
| 52 Haftanın En Yüksek Seviyesi | US$69.29 |
| 52 Haftanın En Düşük Seviyesi | US$22.28 |
| Beta | 1.03 |
| 1 Aylık Değişim | 41.29% |
| 3 Aylık Değişim | 35.73% |
| 1 Yıllık Değişim | 147.68% |
| 3 Yıllık Değişim | -44.63% |
| 5 Yıllık Değişim | -71.29% |
| Halka arzdan bu yana değişim | 261.67% |
Son Haberler & Güncellemeler
Seeking Alpha • Jun 23
Moderna: The Comeback Is Now In Full Swing
Summary Moderna, Inc. is transitioning from Covid-era reliance to a diversified mRNA pipeline, with a cautious buy rating and a suggested entry below $50. MRNA's mFlusiva flu vaccine highlights benefits of mRNA vaccines (speed, flexibility, manufacturing efficiency), showing superior efficacy to incumbents, with FDA approval expected soon and blockbuster potential driving 2027+ revenue ramp. Pipeline catalysts include mCombriax (Covid/Flu combo vaccine), oncology (Intismeran Autogene), and rare disease programs, supported by a solid $5.2B cash position. Key MRNA risks include vaccine sentiment shifts, ongoing litigation, and near-term revenue softness, but long-term growth is underpinned by late-stage assets. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 21
Moderna (MRNA) Stock Could Be 39% Overvalued After FDA Flu Vaccine Backing
Moderna (MRNA) is back in focus after a unanimous FDA advisory panel vote that its investigational mRNA flu vaccine, mFlusiva, has a favorable benefit risk profile in adults 50 and older. See our latest analysis for Moderna. Moderna’s recent regulatory win has arrived after a sharp rebound in the stock, with a 1-year total shareholder return of 146.95% and a year to date share price return of 107.26%, while the 3 and 5 year total shareholder returns remain significantly lower. This suggests...Recent updates
Seeking Alpha • Jun 23
Moderna: The Comeback Is Now In Full Swing
Summary Moderna, Inc. is transitioning from Covid-era reliance to a diversified mRNA pipeline, with a cautious buy rating and a suggested entry below $50. MRNA's mFlusiva flu vaccine highlights benefits of mRNA vaccines (speed, flexibility, manufacturing efficiency), showing superior efficacy to incumbents, with FDA approval expected soon and blockbuster potential driving 2027+ revenue ramp. Pipeline catalysts include mCombriax (Covid/Flu combo vaccine), oncology (Intismeran Autogene), and rare disease programs, supported by a solid $5.2B cash position. Key MRNA risks include vaccine sentiment shifts, ongoing litigation, and near-term revenue softness, but long-term growth is underpinned by late-stage assets. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 21
Moderna (MRNA) Stock Could Be 39% Overvalued After FDA Flu Vaccine Backing
Moderna (MRNA) is back in focus after a unanimous FDA advisory panel vote that its investigational mRNA flu vaccine, mFlusiva, has a favorable benefit risk profile in adults 50 and older. See our latest analysis for Moderna. Moderna’s recent regulatory win has arrived after a sharp rebound in the stock, with a 1-year total shareholder return of 146.95% and a year to date share price return of 107.26%, while the 3 and 5 year total shareholder returns remain significantly lower. This suggests...
Anlatı Güncellemesi • Jun 15
MRNA: Flu Review And Pipeline Execution Risk Are Expected To Restrain Upside
Moderna's updated analyst price target edges higher, with the model fair value moving from $21.00 to about $21.09 as analysts factor in slightly stronger revenue growth expectations and potential upside from norovirus vaccine penetration. Analyst Commentary Recent Street research on Moderna clusters around cautious optimism, with several firms adjusting price targets while still highlighting meaningful risks tied to execution and future growth drivers, especially in vaccines beyond Covid.Anlatı Güncellemesi • Jun 01
MRNA: Flu Review And Litigation Overhang Will Continue To Restrain Upside
Analysts raised Moderna’s fair value estimate from $12.00 to $21.00, citing a series of higher Street price targets and updated assumptions for margins, litigation risk, and future P/E multiples. Analyst Commentary Recent Street research around Moderna has centered on two themes: valuation reset after the litigation settlement and differing views on how much residual legal and execution risk still matters for the stock.
Anlatı Güncellemesi • May 13
MRNA: Future Upside Will Depend On Upcoming Flu Vaccine Authorization Outcome
Narrative Update on Moderna Analysts have collectively raised their Moderna price targets by low to mid single digit dollar amounts, citing updated models that reflect recent litigation settlements, FDA progress on the flu vaccine, and oncology pipeline developments. Together, these factors support a lower fair value estimate of $66.29, a slightly higher discount rate of 7.21%, adjusted revenue growth expectations of 52.59%, a profit margin of 4.12%, and a future P/E assumption of 107.40x.
Anlatı Güncellemesi • Apr 27
MRNA: Litigation Tail And Uncertain Flu Path Will Limit Long-Term Upside
Analysts have lifted the implied fair value estimate for Moderna shares by about $7, citing a reset in litigation risk following the Arbutus and Genevant settlement and refreshed expectations for the flu and broader vaccine pipeline that flow through to higher modeled revenue growth and a richer future P/E multiple. Analyst Commentary Street research on Moderna has been active, with several firms revisiting their models after the Arbutus and Genevant settlement, the Q4 earnings update, and the FDA's decision to review the mRNA-1010 flu vaccine.Anlatı Güncellemesi • Apr 13
MRNA: Flu Review Uncertainty And Legal Tail Risk Will Constrain Upside
Analysts have nudged Moderna's average price target higher by $5, reflecting a mix of renewed confidence in the company's vaccine pipeline after the FDA's reconsideration of its flu shot application and reduced litigation overhang following recent settlement developments. Analyst Commentary Recent research on Moderna clusters around two main themes for you to watch closely: valuation reset around the vaccine pipeline and lingering legal and execution risks tied to the COVID and flu franchises.Anlatı Güncellemesi • Mar 30
MRNA: Litigation Deal And Flu Review Path Will Limit Future Upside
Analyst price targets for Moderna have generally shifted higher, with several firms moving into a $30 to $69 range as they factor in the recent Arbutus settlement, the FDA’s renewed review of the mRNA-1010 flu vaccine with an August 5 PDUFA date, and updated product and oncology pipeline assumptions. Analyst Commentary Street research on Moderna currently reflects a mixed but generally cautious stance, even as litigation and regulatory headlines have reduced some overhangs.Anlatı Güncellemesi • Mar 16
MRNA: Litigation Settlement And Flu Setback Will Constrain Future Upside
Analysts have trimmed Moderna's implied fair value from $15.00 to $12.00 as they factor in a higher discount rate, more moderate profit margins and updated views on revenue growth following recent litigation settlements and regulatory updates. Analyst Commentary Street research around Moderna centers on two themes that matter for you as an investor: the clean-up of legal overhangs and how much confidence to place in the broader vaccine and oncology pipeline.Anlatı Güncellemesi • Mar 02
MRNA: Future Upside Will Hinge On Upcoming Flu Vaccine Approval Decision
Our fair value estimate for Moderna has inched up by about $1.65 per share to $91.97 as analysts update their models around higher projected product sales, a more constructive FDA review path for the mRNA-1010 flu vaccine with an August 5 PDUFA date, and refreshed views on the broader late stage pipeline including oncology. Analyst Commentary Street research on Moderna has leaned more constructive around the updated regulatory path for flu vaccine mRNA-1010, the broader late stage pipeline, and recent quarterly disclosures.Analiz Makalesi • Feb 17
Moderna, Inc. (NASDAQ:MRNA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$40.90
As you might know, Moderna, Inc. ( NASDAQ:MRNA ) just kicked off its latest annual results with some very strong...Anlatı Güncellemesi • Feb 16
MRNA: Future Upside Will Depend On Vaccine Pipeline Execution Outcomes
Analysts have nudged their average price target for Moderna higher by about $3, reflecting updated views on long term revenue potential, profit margins and a higher future P/E multiple following recent research on COVID demand, the broader vaccine pipeline and legal outcomes. Analyst Commentary Recent Street research on Moderna highlights a mix of caution and growing optimism, with several bullish analysts adjusting their models after company updates, legal developments and new financing disclosures.Analiz Makalesi • Feb 02
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 43%
Despite an already strong run, Moderna, Inc. ( NASDAQ:MRNA ) shares have been powering on, with a gain of 43% in the...Anlatı Güncellemesi • Feb 01
MRNA: Cancer Vaccine Risk And Vaccine Backlash Will Restrain Long-Term Upside
The analyst price target for Moderna has increased by about $2 to $38.80, as analysts incorporate updated assumptions for slightly stronger revenue growth, modestly better profit margins, a marginally lower discount rate, and a slightly reduced future P/E multiple. Analyst Commentary Recent Street research on Moderna shows a mix of cautious optimism and ongoing concern.Anlatı Güncellemesi • Jan 18
MRNA: Late Stage Vaccine Outcomes Will Define Future Upside Potential
Narrative update We trim our analyst price target for Moderna from about US$121 to roughly US$87 as analysts factor in lower profit margin expectations, a higher discount rate, cautious views on COVID-related revenue visibility, and a more binary risk profile around key late stage vaccine data, even as some models reflect higher revenue growth assumptions and updated financing terms. Analyst Commentary Recent Street research on Moderna points to a mixed backdrop, with several firms reaffirming cautious stances while still recognizing specific areas where execution and funding choices could support long term value creation.Anlatı Güncellemesi • Jan 04
MRNA: Oncology Progress Will Drive Long-Term Upside Despite Debt And Litigation
Analysts have modestly lifted their price targets on Moderna, with recent revisions such as $15 to $18, $16 to $17, and $32 to $30. These changes collectively reflect slightly improved conviction in the company’s long term revenue growth, gross margin expansion, and strengthened liquidity following new Ares financing, despite ongoing profitability and litigation risks.Anlatı Güncellemesi • Dec 21
MRNA: Oncology Advances And Buyout Optionality Will Offset Debt And Litigation Risks
Analysts have modestly raised their price target on Moderna to align with a slightly higher fair value estimate of about $36.75, citing incremental improvements in long term revenue growth and profitability assumptions supported by recent Investor and Analyst Day updates, revised 2026 to 2028 guidance, and Ares financing. Analyst Commentary Recent Street research reflects a cautious but incrementally more constructive stance toward Moderna, with several firms refining their models following Investor and Analyst Day presentations and the announcement of new financing.Analiz Makalesi • Dec 19
There's No Escaping Moderna, Inc.'s (NASDAQ:MRNA) Muted Revenues Despite A 28% Share Price Rise
Moderna, Inc. ( NASDAQ:MRNA ) shareholders have had their patience rewarded with a 28% share price jump in the last...Anlatı Güncellemesi • Dec 07
MRNA: Oncology Pipeline Progress Will Drive Long Term Upside Despite Litigation Risk
Analysts have modestly lowered their price target on Moderna to about $35.78 from $37.32 per share, reflecting slightly softer long term growth and valuation assumptions. This comes even as recent Investor and Analyst Day updates, new debt financing and evolving oncology data support a more stable cash outlook and gradual margin improvement.Anlatı Güncellemesi • Nov 23
MRNA: Oncology Pipeline Advances Will Drive Renewed Optimism Despite Regulatory Shifts
Analysts have revised their fair value estimate for Moderna down from approximately $40.30 to $37.32. They cited the company’s updated revenue growth projections and cost outlook, despite improvements in profit margins and continued progress across its commercial and research pipelines.Anlatı Güncellemesi • Nov 07
MRNA: Oncology Progress Will Drive Renewed Optimism Amid Regulatory Uncertainties
Moderna's analyst price target was reduced from $18 to $15, as analysts pointed to lower US vaccination trends and ongoing regulatory uncertainties that are impacting the outlook for its vaccine franchises. Analyst Commentary Recent analyst notes have reflected both cautious and optimistic perspectives on Moderna's outlook.Anlatı Güncellemesi • Oct 23
Oncology Advancements And Evolving Policy Will Shape Recovery Amid Regulatory Shifts
Moderna’s analyst price target has been revised downward from $44.25 to $40.30. Analysts cite lower projected revenue growth along with persistent regulatory and profitability challenges, which have been reflected in recent industry commentary.Anlatı Güncellemesi • Sep 04
Pipeline Diversification And Regulatory Momentum Will Unlock Future Potential
Moderna’s consensus price target was held at $44.25 as analysts cited declining US vaccine demand, increased regulatory hurdles for flu/COVID combinations, delayed UK deliveries impacting 2025 guidance, and persistent uncertainty around mRNA vaccine approvals. Analyst Commentary Lowered US vaccination trends for both COVID and flu are reducing addressable market expectations for Moderna’s vaccines.Analiz Makalesi • Jul 18
Moderna, Inc.'s (NASDAQ:MRNA) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Moderna, Inc. ( NASDAQ:MRNA ) shareholders have had their patience rewarded with a 26% share price jump in the last...Yeni Anlatı • May 02
MODERNA (MRNA): WALLSTREET THREW IT OUT - I’LL PICK IT UP AND CASH THE CHECK
Despite the defunding of US governmental research and health services, Moderna remains in a commanding fundamental position. The company that made its name during the COVID-19 pandemic developing andSeeking Alpha • Apr 22
More Downside For Moderna Before The Breakthrough
Summary Moderna's respiratory vaccine sales are not encouraging, and competition is strong, making it difficult to gain market share and sustain revenue. The product pipeline is promising but requires investor patience, with key vaccines in Phase 3 trials but regulatory approvals potentially years away. Financials are sound enough to support long term research, with a significant cash buffer, but oncology research faces regulatory and technical challenges. Shares are likely to go down before any uptrend (2-3 years horizon). Read the full article on Seeking AlphaSeeking Alpha • Mar 31
FDA Shake-Up Rocks Moderna Stock As Regulatory Risks Mount (Downgrade)
Summary Moderna's stock dropped over 10% after the FDA's Dr. Peter Marks resigned, signaling potential increased regulatory scrutiny on vaccines. Moderna's financial health remains strong, with ~$9 billion in cash and investments, but the stock is down 65% since my August rating downgrade. Despite pipeline progress, regulatory uncertainty and intense competition from Pfizer and GSK pose significant risks to Moderna's revenue outlook. Given the negative public perception of mRNA technology and regulatory risks, I downgrade MRNA to "Hold" until more clarity emerges. Read the full article on Seeking AlphaSeeking Alpha • Mar 06
Moderna: Patent Litigation Win Masks Underperformance, Unlikely To Pay Out
Summary Moderna, Inc.'s stock surged 16% yesterday after a German court ruled Pfizer and BioNTech may have violated Moderna's COVID-19 vaccine patent, potentially leading to compensation. Despite the ruling, Pfizer and BioNTech will appeal, while previous court decisions have invalidated related patents, complicating Moderna's legal victory. MRNA's business struggles post-pandemic, with declining revenues and few new products, have made litigation a potentially critical revenue source, which I'd call a red flag. The ongoing legal battles resemble other prolonged patent disputes, highlighting the challenges in monetizing groundbreaking technologies like mRNA and CRISPR. If Moderna had released ten products since 2022, instead of one, it's unlikely yesterday's news would have moved its share price, but this reflects the new reality of messenger-RNA, a technology that hasn't lived up to the hype — yet. Read the full article on Seeking AlphaSeeking Alpha • Feb 14
Moderna, Inc.: Working Hard But Competition Is Working Harder
Summary MRNA's stock surged 4,211% during COVID-19 but has since plummeted to $31, reflecting a significant bubble and raising concerns about its future. Declining revenue and net income, driven by reduced COVID-19 vaccine demand and RSV market challenges, highlight MRNA's financial instability. MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and faces tough competition. Despite negative financials, technical analysis indicates potential support at $28-30, justifying a "hold" position rather than a "sell.". Read the full article on Seeking Alpha
Yeni Anlatı • Feb 09
Vaccine Expansion Plans Could Shape Future Despite Market Challenges And Legal Risks
Strategic product innovation in combining vaccines could enhance long-term revenue streams and international market positioning.Seeking Alpha • Feb 03
Moderna: The Good News Isn't Enough
Summary I initially rated Moderna as a SELL in mid-December, and despite a recent rally, the stock remains volatile. The news flow has been great in January, which mostly caused a rally in the stock. I argue why I don't think anything has changed materially, reinforcing my SELL rating. Despite cost-cutting measures, I am concerned that reducing R&D will hurt Moderna's research capabilities, preferring cuts in SG&A instead. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
Moderna: Can They Benefit From Bird Flu? (Rating Upgrade)
Summary Moderna's stock is down 36.63% due to poor COVID-19 vaccine sales and lack of promising alternatives, but bird flu presents asymmetric upside potential. The company's cost-cutting measures may hinder innovation, but rising COVID cases and bird flu risks could uniquely benefit Moderna if a pandemic occurs. Moderna's bird flu vaccine development, supported by a U.S. government grant, could be a game changer if the bird flu spreads significantly. With only a 5% chance of a bird flu pandemic, I believe Moderna is a hold, awaiting further developments on the bird flu's virality. Read the full article on Seeking AlphaSeeking Alpha • Dec 31
Moderna: 2025 Contrarian Play
Summary Moderna ends 2024 as one of the worst-performing Nasdaq-100 stocks, but it presents a contrarian play for 2025 due to vaccine catalysts. The stock is down to $40 with a $15 billion market cap, despite having $3+ billion in revenue and a promising pipeline. Moderna's spending issue is a concern, but the potential of its CMV and cancer vaccines could significantly boost sales and justify current R&D expenses. Investors should consider buying the beaten-down stock around $40, anticipating higher sales and multiple big approvals in the coming years. Read the full article on Seeking AlphaSeeking Alpha • Dec 18
Moderna: Cutting Costs Might Not Be Enough
Summary Moderna, a leader in mRNA medicine, developed one of the earliest COVID-19 vaccines, with Spikevax being its first commercial product. The company's mRNA platform enables the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. MRNA has struggled in the post-COVID era, making its capacity to generate free cash flows doubtful. Read the full article on Seeking AlphaSeeking Alpha • Nov 22
Moderna's Fresh Blow As RFK Heads To HHS - A Tough 2025 May Be In Store
Summary Moderna, Inc.'s stock has plummeted over 75% in 2024, driven by disappointing earnings, reduced revenue forecasts, and now the threat of a vaccine skeptic, RFK Jr.'s potential confirmation to lead HHS. Despite two commercialized vaccines and positive Phase 3 results for others, Moderna faces uncertainty in achieving profitability before 2028, with significant R&D expenses and competitive pressures. The private COVID-19 vaccine market is considered stable but limited, and the RSV vaccine faces competition from GSK and Pfizer, and likely restriction to a once-every 3-year dose. A potential acquisition by a Big Pharma like Merck could bring fresh R&D perspectives, but Moderna may need to consider further program cuts to achieve profitability in a shorter time-frame. Read the full article on Seeking AlphaSeeking Alpha • Oct 22
Moderna: Assessing The Impact Of GSK's Patent Lawsuit
Summary GSK's lawsuit against Moderna over lipid nanoparticle technology could severely impact Moderna's revenue from Spikevax and mResvia, and delay their breakeven point. The lawsuit adds uncertainty to MRNA's already declining stock, increasing short-selling activity and potentially leading to prolonged negative headlines. Despite the legal risks, I plan to trade MRNA, looking for a reversion play if the ticker breaks its downtrend with elevated volume. I am lowering my MRNA conviction level from 3 to 2 out of 5 and moving it to the speculative “Bio Boom” portfolio. Read the full article on Seeking AlphaSeeking Alpha • Sep 20
Moderna: Still Bullish View
Summary Moderna's stock has fallen due to the weak management revenue guidance, but I remain positive about its long-term potential. Key developments include the next-gen COVID-19 vaccine, the RSV vaccine, and promising pipeline drugs like the cytomegalovirus and cancer vaccines. Management's 2024 revenue guidance is conservative. I expect Moderna to outperform it. My fair valuation of Moderna stock was adjusted to $149. Read the full article on Seeking AlphaHissedar Getirileri
| MRNA | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | 5.2% | 7.5% | -2.6% |
| 1Y | 147.7% | 40.6% | 20.0% |
Getiri vs. Endüstri: MRNA geçen yıl % 40.6 oranında getiri sağlayan US Biotechs sektörünü aştı.
Getiri vs Piyasa: MRNA geçen yıl % 20 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| MRNA volatility | |
|---|---|
| MRNA Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: MRNA son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: MRNA 'nin haftalık oynaklığı ( 10% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2010 | 4,700 | Stéphane Bancel | www.modernatx.com |
Bir biyoteknoloji şirketi olan Moderna, Inc. Amerika Birleşik Devletleri, Avrupa ve uluslararası alanda mesajcı RNA ilaçları sağlamaktadır. Şirketin solunum aşıları arasında spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, mevsimsel grip, kombinasyon ve pandemik grip aşısı; latent aşılar sitomegalovirüs, epstein-barr virüsü ve insan immün yetmezlik virüsü aşılarını; enterik virüsler norovirüsü; halk sağlığı aşıları Zika, Nipah ve Mpox aşılarını; ve lyme aşıları gibi bakteriyel hastalık aşılarını içerir. Ayrıca intismeran autogene, kanser antijen terapisi, t-hücre engager ve hücre terapisi arttırıcı gibi onkoloji terapötikleri ve propiyonik ve metilmalonik asidemi ve kistik fibrozis gibi nadir hastalık ürünleri de sunmaktadır.
Moderna, Inc. Temel Bilgiler Özeti
| MRNA temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$23.71b |
| Kazançlar(TTM) | -US$3.19b |
| Gelir(TTM) | US$2.23b |
12.0x
P/S Oranı-8.4x
F/K OranıMRNA aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| MRNA gelir tablosu (TTM) | |
|---|---|
| Gelir | US$2.23b |
| Gelir Maliyeti | US$3.78b |
| Brüt Kâr | -US$1.55b |
| Diğer Giderler | US$1.64b |
| Kazançlar | -US$3.19b |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -8.05 |
| Brüt Marj | -69.89% |
| Net Kâr Marjı | -143.55% |
| Borç/Özkaynak Oranı | 8.0% |
MRNA uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/06/26 06:25 |
| Gün Sonu Hisse Fiyatı | 2026/06/26 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Moderna, Inc. 42 Bu analistlerden 22, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | Argus Research Company |
| Eliana Merle | Barclays |
| Huidong Wang | Barclays |